⌘K

Login Start Free

Home/Filings/4/0001127602-24-028232

4//SEC Filing

Parsey Merdad 4

Accession 0001127602-24-028232

CIK 0000882095other

View on SEC.gov Company Profile

Filed

Nov 28, 7:00 PM ET

Accepted

Nov 29, 8:10 PM ET

Size

18.4 KB

Accession

0001127602-24-028232

Insider Transaction Report

Form 4

Period: 2024-11-27

GILEAD SCIENCES, INC.GILD

Chief Medical Officer

Transactions

Exercise/Conversion
Common Stock
2024-11-27$65.38/sh+88,119$5,761,220→ 245,012 total
Sale
Common Stock
2024-11-27$92.00/sh−88,119$8,106,948→ 99,599 total
Sale
Common Stock
2024-11-27$92.00/sh−10,399$956,708→ 80,801 total
Sale
Common Stock
2024-11-27$91.80/sh−5,200$477,381→ 94,399 total
Exercise/Conversion
Non-qualified Stock Option (Right to Buy)
2024-11-27−57,294→ 64,376 total
Exercise: $57.92Exp: 2032-03-10→ Common Stock (57,294 underlying)
Exercise/Conversion
Non-qualified Stock Option (Right to Buy)
2024-11-27−88,119→ 196 total
Exercise: $65.38Exp: 2029-11-10→ Common Stock (88,119 underlying)
Sale
Common Stock
2024-11-27$91.80/sh−3,199$293,679→ 91,200 total
Exercise/Conversion
Common Stock
2024-11-27$57.92/sh+57,294$3,318,468→ 156,893 total
Sale
Common Stock
2024-11-27$91.79/sh−57,294$5,259,297→ 187,718 total

Footnotes (4)

[F1]Sale prices reported for the transactions reported here range from $91.451 to $92.095. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
[F2]Sale prices reported for the transactions reported here range from $91.458 to $92.04. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
[F3]Sale prices reported for the transactions reported here range from $91.451 to $92.035. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
[F4]The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Documents

1 file

4
form4.xmlPrimary
PRIMARY DOCUMENT

Issuer

GILEAD SCIENCES, INC.

CIK 0000882095

Entity typeother

Related Parties

1

filerCIK 0001792150

Filing Metadata

Form type: 4
Filed: Nov 28, 7:00 PM ET
Accepted: Nov 29, 8:10 PM ET
Size: 18.4 KB

View on SEC.gov